Skip to content

Beximco Pharma Profit Jumps 31% on Sales Growth

Beximco Pharma's audited results show profit after tax rising 30.9% on 14.5% higher sales, with the board recommending a 60% cash dividend and year-end cash balances nearly quadrupling.

Beximco Pharmaceuticals (AIM:BXP) reported a 30.9% rise in profit after tax to BDT 9,160.8m (£56.6m) for the year to 30 June 2026, on net revenue up 14.5%. The Bangladesh-based maker of generic medicines and active pharmaceutical ingredients published its audited results this morning.

Revenue reached BDT 56,265.9m (£347.5m), against BDT 49,120.4m (£295.6m) a year earlier. Domestic sales, the bulk of the business, rose 15.1% to BDT 51,852.5m, while exports grew 8.3% to BDT 4,413.4m. Sterling figures use the company’s own average rates: £1 to BDT 161.9021 for the latest year and BDT 166.1585 for the year before.

Profit grew about twice as fast as sales. Gross profit climbed 22.9%, and finance cost fell from BDT 991.7m to BDT 656.4m. Earnings per share rose to BDT 20.17 from BDT 15.56, and profit after tax a year earlier was BDT 6,998.9m (£42.1m).

The balance sheet strengthened. Operating cash flow was BDT 9,514.8m, and closing cash reached BDT 6,668.0m, up from BDT 1,700.1m. Total liabilities fell to BDT 14,945.2m from BDT 16,162.6m. The board recommends a 60% cash dividend, equal to BDT 6.00 per share; the announcement gives no payment dates.

Bar chart of Beximco Pharma net revenue, profit from operations and profit after tax, FY2025 vs FY2026, BDT million
Beximco Pharma revenue and profit, years ended 30 June, BDT million. Source: company results.

Operationally, the group launched Eletriptan tablets, an anti-migraine treatment, in the US and Sotalol tablets in Canada, and won 43 registrations for 36 products across 18 countries. Managing Director Iqbal Ahmed singled out Triko, which the company describes as the world’s first and only generic copy of the cystic fibrosis drug Trikafta.

On the outlook, Ahmed pointed to continuing pressure from the economy. The company gave no explicit forward guidance.

Whilst we continue to experience ongoing global macro-economic challenges, we remain focused on executing on our strategy and navigating the evolving business environment.

Iqbal Ahmed, Managing Director, Beximco Pharma

Asktraders News Team
Asktraders News Team
Team Member

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.